
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
The Outlook for CAR-Modified T Cells
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Read more about CAR-modified T cells and other immunotherapies for B-cell malignancies > >
Articles in this issue
over 11 years ago
B-Cell Malignancies Faring Well With Immunotherapiesover 11 years ago
Update on Immunotherapy and Targeted Combination Therapiesover 11 years ago
How Immunotherapies are Changing the Treatment of Melanomaover 11 years ago
Progress Made With PD-L1 as Predictive Biomarkerover 11 years ago
Oncolytic Viral Therapies About to Spreadover 11 years ago
The Future of Immunotherapy Treatments in Lung Cancerover 11 years ago
Checking in on Checkpoint Inhibitors






































